Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M701823200 on October 2, 2007

J. Biol. Chem., Vol. 282, Issue 49, 35722-35732, December 7, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/49/35722    most recent
M701823200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saavedra, L.
Right arrow Articles by de Chaves, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saavedra, L.
Right arrow Articles by de Chaves, E. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Internalization of β-Amyloid Peptide by Primary Neurons in the Absence of Apolipoprotein E*Formula

Lucila Saavedra{ddagger}§, Amany Mohamed{ddagger}§, Victoria Ma{ddagger}, Satyabrata Kar§, and Elena Posse de Chaves{ddagger}§1

From the Departments of {ddagger}Pharmacology and Medicine and the §Centre for Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada

Received for publication, March 1, 2007 , and in revised form, September 11, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Extracellular accumulation of β-amyloid peptide (Aβ) has been linked to the development of Alzheimer disease. The importance of intraneuronal Aβ has been recognized more recently. Although considerable evidence indicates that extracellular Aβ contributes to the intracellular pool of Aβ, the mechanisms involved in Aβ uptake by neurons are poorly understood. We examined the molecular mechanisms involved in Aβ-(1–42) internalization by primary neurons in the absence of apolipoprotein E. We demonstrated that Aβ-(1–42) is more efficiently internalized by axons than by cell bodies of sympathetic neurons, suggesting that Aβ-(1–42) uptake might be mediated by proteins enriched in the axons. Although the acetylcholine receptor {alpha}7nAChR, previously suggested to be involved in Aβ internalization, is enriched in axons, our results indicate that it does not mediate Aβ-(1–42) internalization. Moreover, receptors of the low density lipoprotein receptor family are not essential for Aβ-(1–42) uptake in the absence of apolipoprotein E because receptor-associated protein had no effect on Aβ uptake. By expressing the inactive dynamin mutant dynK44A and the clathrin hub we found that Aβ-(1–42) internalization is independent of clathrin but dependent on dynamin, which suggests an endocytic pathway involving caveolae/lipid rafts. Confocal microscopy studies showing that Aβ did not co-localize with the early endosome marker EEA1 further support a clathrin-independent mechanism. The lack of co-localization of Aβ with caveolin in intracellular vesicles and the normal uptake of Aβ by neurons that do not express caveolin indicate that Aβ does not require caveolin either. Instead partial co-localization of Aβ-(1–42) with cholera toxin subunit B and sensitivity to reduction of cellular cholesterol and sphingolipid levels suggest a caveolae-independent, raft-mediated mechanism. Understanding the molecular events involved in neuronal Aβ internalization might identify potential therapeutic targets for Alzheimer disease.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In brains of individuals with Alzheimer disease (AD),2 β-amyloid peptide (Aβ) aggregates and accumulates as toxic fibrils in neuritic plaques and toxic soluble oligomers (1). Aβ is a 39–43-amino acid peptide derived from the proteolytic cleavage of the amyloid precursor protein (APP) (2). The amyloid cascade hypothesis predicts that a gradual increase of Aβ-(1–42) levels in brain interstitial fluid (3, 4) may lead to Aβ oligomerization and eventually to Aβ fibrillization (5). Current evidence indicates that intraneuronal accumulation of Aβ is an early pathological biomarker for the onset of AD and may contribute to the cascade of neurodegenerative events (6). The observation that cortical neurons that accumulate Aβ-(1–42) in brains of Down syndrome patients are apoptotic (7, 8) provided additional indications of the importance of intracellular Aβ (7, 8). Furthermore, microinjection of Aβ-(1–42) or cDNA encoding Aβ-(1–42) in cultured human neurons resulted in neurotoxicity (9). Besides, in the triple transgenic mouse model for AD there is a correlation between long term potentiation abnormalities and intraneuronal Aβ accumulation, all of which take place before the appearance of plaques or tangles (10). Intracellular accumulation of Aβ-(1–42) results from one or a combination of the following processes: decreased Aβ degradation (disruption of the ubiquitin-proteasome system), increased intracellular generation of Aβ, and increased uptake of Aβ from an external source (11). Both increased intracellular Aβ generation and uptake of extracellular Aβ are consistent with the endosomal/lysosomal localization of intracellular Aβ (12, 13).

Deposits of oligomeric Aβ are preferentially found on distal axons and synapses in mouse brains suggesting that these structures might represent the cellular entry points for Aβ (14). In support of the role of axons in Aβ-induced neurotoxicity we have demonstrated previously that neurons exposed to Aβ exclusively in distal axons are more susceptible to apoptosis than neurons exposed only in cell bodies suggesting the possible involvement of axons in Aβ uptake (15). Nevertheless to our knowledge direct demonstration of Aβ uptake by axons is still missing.

In the brain, plasma, and cerebrospinal fluid as well as in senile plaques Aβ is associated to apolipoprotein E (apoE) (16–18). Besides a pool of free Aβ likely exists. Internalization of the complex Aβ-apoE has been extensively studied (19–21); however, the mechanism that mediates uptake of Aβ that is not complexed to apoE is largely unknown. This pool likely increases considerably during AD development. Therefore, targeting free Aβ internalization might represent a way to regulate intracellular Aβ levels. In the present study, we examined the molecular mechanisms of Aβ-(1–42) internalization by primary neurons in the absence of lipoproteins.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents and Antibodies—Leibovitz L15-CO2 culture medium was from Invitrogen. Mouse NGF (2.5 S) was purchased from Alomone Laboratories Ltd. (Jerusalem, Israel). NGF antibody (sheep anti-NGF) was purchased from Cedarlane Laboratories Ltd. (Hornby, Ontario, Canada). Fumonisin B1 was obtained from Biomol International. Mouse monoclonal anti-human Aβ (clone 4G8) was from Signet. Antibodies against {alpha}7nAChR and EEA1 were kindly provided by Dr. Jhamandas (University of Alberta) and Dr. Wang (University of Alberta), respectively. Goat anti-mouse IgG secondary antibody, EZ-Link NHS-S-S-biotin and ImmunoPure immobilized streptavidin were purchased from Pierce. Rabbit anti-caveolin antibody was purchased from BD Transduction Laboratories. Alexa594-conjugated secondary antibody, Alexa594-conjugated cholera toxin subunit B (CTxB), DiI-LDL, and the Amplex Red cholesterol assay kit were purchased from Molecular Probes (Eugene, OR). Immobilon polyvinylidene difluoride was from Bio-Rad. Enhanced chemiluminescence reagents were from Amersham Biosciences. Aβ-(1–42) was purchased from American Peptide Co. (Sunnyvale, CA). The same lot number was used throughout the studies unless specified. Fluorescein-labeled Aβ-(1–42) (fluo-Aβ-(1–42)) was purchased from AnaSpec (San Jose, CA). Human β-amyloid (Hu Aβ42) enzyme-linked immunosorbent assay kit (KHB 3441) was purchased from BIOSOURCE International, Inc. (Camarillo, CA). {alpha}-Bungarotoxin ({alpha}-BTx) was purchased from Sigma-Aldrich. Filipin complex was purchased from Sigma. All other reagents were from Fisher.

Culture of Neurons—Sympathetic neurons were isolated from superior cervical ganglia of newborn Harlan Sprague-Dawley rats and cultured in compartmentalized dishes as before (22). Dissociated neurons (0.3 ganglia/dish) were plated in the center compartment. Within 1–2 days, axons elongated along the tracks and entered the side compartments that contained medium supplemented with 50 ng/ml NGF. Medium supplied to the center compartment contained 2.5% rat serum, 1 mg/ml ascorbic acid, 10–15 µM cytosine arabinoside, and 10 ng/ml NGF. After 5–6 days cytosine arabinoside treatment was discontinued, and NGF was confined to the side compartments. For some experiments sympathetic neurons were cultured in 8-well chamber slides or 24-well dishes. Sympathetic neurons from caveolin-1 knock-out (Cav1–/–) and control ((B6 129 SF2/J) (Cav1+/+)) mice (The Jackson Laboratory, Bar Harbor, ME) were isolated and cultured as above. Experiments started at day 7–8 in culture. Rat basal forebrain cholinergic neurons were generously provided by Dr. Jhamandas (University of Alberta) and were prepared as before (23). Experiments started at day 3 in culture. Before the treatments neurons were rinsed several times with medium without serum, and the experimental treatments were performed in the absence of serum.

Aβ-(1–42) Preparations—Non-fluorescent and fluorescein-conjugated Aβ-(1–42) peptide were prepared according to published protocols (24). Briefly Aβ-(1–42) peptide was initially dissolved to 1 mM in hexafluoroisopropanol and separated into aliquots in sterile microcentrifuge tubes. Hexafluoroisopropanol was dried under a stream of N2, and the peptide film was desiccated at –20 °C. The peptide was resuspended in Me2SO at a concentration of 5 mM. L15-CO2 medium (phenol red-free, antibiotic-free, and serum-free) was added to bring the peptide to a final concentration of 100 µM and incubated at 4 °C for 24 h. To prepare biotinylated Aβ (bio-Aβ-(1–42)), a solution of 100 µM Aβ-(1–42) was treated with a 1.5 mg/ml concentration of the membrane-impermeable derivative of biotin (sulfo-NHS-S-S-biotin) in Leibovitz L15-CO2 medium (phenol red-free, antibiotics free, serum free) according to the manufacturer's specifications. The reaction was stopped by adding 100 µl of 250 mM glycine. The biotinylated peptide was diluted in Leibovitz L15-CO2 medium to the appropriate concentration. All Aβ preparations used were similar to those characterized previously (24) in that they contain monomers and oligomers of Aβ but do not contain fibrils (see supplemental Fig. 1, A and B). Fluo-Aβ-(1–42) and bio-Aβ-(1–42) induced neuronal apoptosis like the non-modified peptide (supplemental Fig. 1).

Immunoblotting—For the detection of Aβ, proteins were separated by SDS-PAGE on 12% polyacrylamide gels containing 0.1% SDS using two buffers system (25). For all other experiments the concentration of polyacrylamide gels was 10% containing 0.1% SDS. Transfer of proteins to polyvinylidene difluoride membranes was performed overnight at 4 °C in 25 mM Tris, 192 mM glycine, 16% methanol buffer, pH 8.3. Membranes were blocked for 1 h in Tris-buffered saline, 0.1% Tween 20 (TTBS) containing 5% nonfat milk (blocking buffer) and incubated overnight in the primary antibody solution prepared in TTBS containing 5% nonfat milk. Primary antibodies for Aβ (4G8) (1:1000) and anti-{alpha}7nAChR (1:1000) were used. Membranes were washed two times with Tris-buffered saline, two times with TTBS, and two times with Tris-buffered saline and then incubated for 1 h with the secondary antibody (1:2000) in blocking buffer at room temperature with gentle agitation. Immunoreactivity was detected by ECL (Amersham Biosciences).

Receptor Binding Assays—Radioligand binding assay in cultured neuronal membranes was performed as described earlier (26). In brief, cultured neurons were scraped into ice-cold Tris-HCl (50 mM, pH 7.4) and then homogenized by passing the cell lysates several times through a Pasteur pipette. Membranes were centrifuged three times and then incubated for 2 h at 22 °C in Tris-HCl buffer (50 mM, pH 7.4) containing 1 mM MgCl2, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1% bovine serum albumin, and 1 nM 125I-{alpha}-BTx (2000 Ci/mmol, Amersham Biosciences) as mentioned before (27). Nonspecific binding was determined in the presence of 1 µM unlabeled {alpha}-BTx. Displacement of 125I-{alpha}-BTx binding sites was also simultaneously studied in the presence or absence of 100 µM nicotine and 5 µM Aβ-(1–42). Incubations were terminated by rapid filtration using a cell harvester filtering apparatus, and then radioactivity was measured using a {gamma} counter. Binding experiments were performed four times, each in triplicate, and data are represented as percentage of specific binding.

Adenoviral Infection—Recombinant adenoviruses expressing the tetracycline-regulated chimeric transcription activator (tTA), hemagglutinin-tagged wild type dynamin, hemagglutinin-tagged dynK44A mutant, and T7-tagged clathrin hub were prepared by Dr. Altschuler (28) and obtained from Dr. Nabi (University of British Columbia). To enhance the infection, viral stocks were preincubated with polylysine (29). Infection of sympathetic neurons with serial dilutions of adenovirus constructs was used to determine the minimum amount of virus necessary to infect the majority of the neuronal population (>80%). Titration was performed using QuickTiter Adenovirus Titer Immunoassay kit (Cell Biolabs, Inc.-Cedarlane Laboratories Ltd., Ontario, Canada). Neurons cultured in compartmentalized dishes were infected with a multiplicity of infection of 100 in 50 µl of L15-CO2 medium containing 50 ng/ml NGF, 2.5% rat serum, and 1 mg/ml ascorbic acid added to the cell body-containing compartment for 24 h. The next day the medium was replaced with fresh medium. The experiments were initiated after 48–72 h of viral protein expression. To examine the expression of the recombinant proteins, cellular material from control and infected cultures was collected directly in modified Laemmli sample buffer and analyzed by immunoblot.

Assessment of Aβ Internalization by Immunofluorescence and Confocal Microscopy—Fluo-Aβ-(1–42) was provided to sympathetic neurons cultured in three-compartment cultures or 8-well slides. The internalization of fluo-Aβ-(1–42) in living neurons was examined using a Nikon TE300 inverted fluorescence microscope equipped with a Nikon digital camera, DXM-1200 (Nikon, Toronto, Ontario, Canada). Images were taken and analyzed using Northern Eclipse Version 7.0 image capture and analysis software (Empix Imaging, Mississauga, Ontario, Canada). For confocal microscopy studies, after the indicated treatments in each experiment, culture medium was removed, and cells were fixed in 4% paraformaldehyde for 20 min, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline for 15 min, and then blocked using 0.1% gelatin in phosphate-buffered saline (blocking buffer) for 1 h. For detection of caveolin, primary rabbit anti-caveolin (1:250) and secondary Alexa594-labeled goat anti-rabbit antibody prepared in blocking buffer (1:1000) were used. Pictures were taken using a Zeiss LSM 510 confocal laser-scanning microscope equipped with an S-Fluor 40x/1.3 oil objective using appropriate filter sets and excitation wavelengths. Co-localization was quantified using Metamorph software. For both channels, the best fit lower threshold value to remove most background signal was determined using the threshold tool.

Assessment of Aβ Internalization Using Biotinylated Aβ—Biotinylated Aβ was added to neurons, and internalization was allowed to occur by incubation at 37 °C. At the end of the experiment, the biotin moiety from Aβ that remained outside the neurons was cleaved by reducing its disulfide linkage with glutathione buffer (two times for 15 min at 4 °C). Excess glutathione was inactivated using 5 mg/ml iodoacetamide in phosphate-buffered saline (two times for 5 min at 4 °C) (30). Finally neurons were lysed using RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% (v/v) Nonidet P-40, 2 mM EDTA, pH 8.0, and 2 mM MgCl2) containing protease inhibitor mixture tablets (Complete Mini, Roche Diagnostics). The internalized bio-Aβ-(1–42) protected from the cleavage buffer was pulled down with ImmunoPure immobilized streptavidin beads. The samples were eluted from the beads with boiling Laemmli sample buffer (40 mM Tris-HCl, pH 6.8, 1% SDS, 4% 2-mercaptoethanol, 10% glycerol, and 0.002% bromphenol blue), resolved by SDS-PAGE (25), and immunoblotted with 4G8 antibody against Aβ as above.

Assessment of Aβ Internalization by Enzyme-linked Immunosorbent Assay—Aβ-(1–42) was provided to sympathetic neurons cultured in three-compartment cultures. Cellular material from the cell body-containing compartment of three dishes of the same treatment was harvested in 0.05 N NaOH. The mass of Aβ-(1–42) in cell bodies was quantified using sandwich enzyme-linked immunosorbent assay according to the manufacturer's specifications. Incubation with chromogen substrate produced a colorimetric response (450 nm) measured using a SpectroMax (Molecular Devices, Sunnyvale, CA) microtiter plate reader. Protein content was determined by BCA assay (Pierce). The data are presented as pg of Aβ/µg of protein.

Detection of Nuclear Apoptosis—Apoptotic cell death was identified by nuclear staining with Hoechst 33258 as described previously (15). Nuclei were visualized using a Nikon TE300 inverted fluorescence microscope equipped with a Nikon digital camera, DXM-1200. Images were analyzed using Northern Eclipse Version 7.0 image capture and analysis software (Empix Imaging). Five hundred to 1000 neurons per treatment were counted by an observer "blinded" to the neuronal treatment.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Aβ-(1–42) Is Preferentially Internalized by Axons, Is Retrogradely Transported, and Accumulates in Cell Bodies—We examined the ability of neurons to internalize Aβ in the absence of ligands (apoE and {alpha}2-microglobulin) that bind to known surface receptors. Basal forebrain and sympathetic neurons, two neuronal types that respond similarly to Aβ-(1–42) (15), were able to internalize fluo-Aβ-(1–42) (Fig. 1A). Due to its hydrophobic nature, a significant portion of Aβ remained attached to the cell surface, and therefore it was difficult to differentiate plasma membrane-bound Aβ from internalized Aβ. Therefore, we used a biotin internalization assay to confirm Aβ uptake. In this assay the biotin moiety of Aβ that remains bound to the extracellular aspect of the plasma membrane is cleaved. Hence when streptavidin is used to separate bio-Aβ-(1–42) only internalized Aβ, which is protected from cleavage, is recovered. In this way, we confirmed that Aβ-(1–42) is internalized by neurons in a time-dependent manner (Fig. 1B). To make sure that apoE was absent in our studies, in addition to performing the experiments in the absence of serum we confirmed that neurons were not making apoE even when treated with Aβ (supplemental Fig. 2).


Figure 1
View larger version (74K):
[in this window]
[in a new window]

  		FIGURE 1.
Aβ-(1–42) is internalized preferentially by axons. A, rat basal forebrain and sympathetic neurons were incubated with 5 µM fluo-Aβ-(1–42). After 18 h, cells were washed extensively and visualized under fluorescence and phase-contrast microscopy as indicated under "Experimental Procedures." Bar, 20 µm. B, sympathetic neurons cultured in 24-well plates were incubated with 5 µM bio-Aβ-(1–42) at 37 °C for different times. Internalized Aβ was analyzed after cleavage of biotin moiety as described under "Experimental Procedures." As control, samples of bio-Aβ-(1–42) before (b-Aβ) and after cleavage (b-Aβ/cleaved) were included. A lane without Aβ is also shown. The experiments were performed three times with comparable results. C, sympathetic neurons plated in compartmentalized dishes were incubated with 5 µM fluo-Aβ-(1–42) in either DAX (a–d) or CB (e–h). After 18 h, the cells were analyzed by microscopy. The experiment was performed at least three times with similar results. Bar, 20 µm. D, quantification by enzyme-linked immunosorbent assay of total Aβ in cell bodies of neurons treated with Aβ-(1–42) in the distal axon-containing compartment. Data are expressed as means ± S.D. of three independent experiments. Statistically significant differences from cultures given no fluo-Aβ-(1–42) (p < 0.001) are indicated by *. E, sympathetic neurons were cultured and treated as in C, but bio-Aβ-(1–42) was used. At the end of the incubation internalized Aβ was examined as in B. IB, immunoblot; P, precipitation; AX, axons.

 
Previous studies in mouse brain using specific immunodetection indicated that Aβ localizes to cell processes, especially to axon terminals, suggesting the involvement of axons in Aβ uptake (31, 32). To investigate Aβ internalization by cell bodies and axons separately, we chose a compartmentalized culture system (33), which allows the selective treatment of distal axons or cell bodies with Aβ (15). When fluo-Aβ-(1–42) was added to the distal axon-containing compartment (DAX) only, we observed significant Aβ internalization and retrograde transport to the cell body/proximal axon-containing compartment (CB) (Fig. 1C, a–d). Moreover, we detected a dramatic increase of the mass of Aβ in the cell bodies, confirming Aβ uptake and transport (Fig. 1D). In contrast, when fluo-Aβ-(1–42) was added exclusively to CB, there was significantly less Aβ internalization, and Aβ anterograde transport was almost negligible (Fig. 1C, e–h). Unfortunately we could not quantify the mass of Aβ when it was provided to cell bodies because the small amount of Aβ associated to the surface of cell bodies was sufficient to interfere with the determination. To confirm the preferential Aβ uptake by axons, we treated sympathetic neurons in DAX or CB with bio-Aβ-(1–42) and examined Aβ internalization after cleavage of extracellular Aβ as indicated above. We were able to detect bio-Aβ-(1–42) only in neurons given Aβ in the distal axons (Fig. 1E). The fact that Aβ internalization occurs preferentially through axons suggests that the mechanism that mediates Aβ uptake is regulated and likely involves proteins that are enriched in the axons.

{alpha}-Bungarotoxin and Receptor-associated Protein Do Not Affect Aβ Internalization—A receptor previously implicated in Aβ internalization is the {alpha}7nAChR (34). Hence we investigated whether {alpha}7nAChR was enriched in distal axons of neurons cultured in three-compartment dishes. In parallel, we examined the expression of {alpha}7nAChR in basal forebrain neurons and sympathetic neurons cultured in regular dishes. As expected, {alpha}7nAChR was highly expressed in basal forebrain neurons and in sympathetic neurons cultured under cholinergic (with leukemia inhibitory factor) as well as adrenergic (without leukemia inhibitory factor) conditions (Fig. 2A). Importantly we found a dramatic enrichment of this receptor in distal axons compared with cell bodies/proximal axons, making {alpha}7nAChR a good candidate to mediate Aβ uptake. However, competition binding experiments showed that 5 µM Aβ-(1–42) was unable to significantly compete with 125I-{alpha}-BTx receptor binding sites in membranes prepared from sympathetic neurons (Fig. 2B). In contrast, 1 µM unlabeled {alpha}-BTx (i.e. nonspecific binding) and 10 µM nicotine potently displaced 125I-{alpha}-BTx binding, thus indicating that the sites recognized by this ligand represent a subset of nicotinic receptors. These data, in agreement with a recent report (35), suggest that Aβ does not compete with the {alpha}7nAhR binding site. Accordingly in neurons given {alpha}-BTx together with fluo-Aβ-(1–42) there was no decrease in Aβ internalization (Fig. 2C). All together our data suggest that {alpha}7nAChR does not mediate Aβ uptake at least in neurons under our experimental conditions.


Figure 2
View larger version (76K):
[in this window]
[in a new window]

  		FIGURE 2.
Neither the acetylcholine receptor {alpha}7nAChR nor lipoprotein receptors of the LDLr family mediate Aβ uptake in the absence of apoE. A, expression of {alpha}7nAChR was analyzed by SDS-PAGE and immunoblotting (IB) as described under "Experimental Procedures." Equal amounts (30 µg) of cellular material from basal rat forebrain neurons (BFCN), rat sympathetic neurons cultured in 24-well plates in the presence of leukemia inhibitory factor (+LIF) or the absence of leukemia inhibitory factor (–LIF), and rat sympathetic neurons in three-compartment dishes; DAX and CB were used. B, neuronal membranes from rat sympathetic neurons were prepared and incubated with 1 nM 125I-{alpha}-BTx in the absence and presence of 5 µM Aβ-(1–42) as indicated under "Experimental Procedures." Nonspecific binding was determined in the presence of 1 µM unlabeled {alpha}-BTx. The data display specific binding in the presence of Aβ for three separate experiments (Exp1–3) and the corresponding average (Av). In the same experiments 100 µM nicotine was able to completely displace 125I-{alpha}-BTx binding sites (not shown). C, sympathetic neurons cultured in three-compartment dishes were left untreated (control) or pretreated with 10 µM {alpha}-BTx for 30 min at 37 °C followed by a co-incubation with {alpha}-BTx and 5 µM fluo-Aβ-(1–42) in DAX. After 12 h, the cell body-containing compartment was analyzed in live neurons. The experiment was repeated twice with comparable results. Bar, 20 µm. D, sympathetic neurons cultured in three-compartment dishes were left untreated (control) or pretreated with 1 µM RAP for 1 h at 37 °C followed by a co-incubation with 1 µM RAP and 5 µM fluo-Aβ-(1–42) (a–d) or 1 µM RAP and 50 µg/ml of DiI-LDL (e–h) in DAX. After 18 h, the cell body-containing compartment was analyzed in live neurons. The experiment was repeated twice with similar results. Bar, 20 µm. AX, axons.

 
A second group of receptors that distribute differently to cell bodies and axons (36) and that have been linked to Aβ internalization is the LDL receptor (LDLr) family. Internalization through this receptor is blocked by the chaperone protein receptor-associated protein (RAP) (37–39). RAP, at a concentration that has been proven to inhibit ligand interaction of all LDLr family members (40), was unable to inhibit fluo-Aβ-(1–42) uptake and transport (Fig. 2D). To prove that RAP effectively inhibits LDLr in sympathetic neurons under our experimental conditions, we examined uptake and transport of LDL particles labeled with DiI, which are natural ligands of these receptors. As expected RAP caused a dramatic decrease in the internalization of LDL (Fig. 2D). The lack of effect of RAP on Aβ uptake and transport suggests that LDLr family members are not required for Aβ internalization in the absence of apoE.

Aβ Uptake Is Dynamin-dependent but Clathrin-independent—Internalization of Aβ in a complex with LDL receptor ligands is mediated by coated pits. We aimed to identify whether clathrin was required for Aβ uptake in the absence of apoE. Clathrin- and caveolae/lipid raft-mediated endocytosis remain the two best characterized mechanisms of ligand-receptor internalization (41). Both mechanisms require the GTPase dynamin, but caveolae/lipid raft-mediated endocytosis is independent of clathrin. Using adenoviral infection we expressed in neurons dominant-negative constructs of dynamin or overexpressed the clathrin hub peptide that inhibits clathrin-mediated endocytosis. For control we expressed wild type dynamin. Under these conditions we investigated the internalization route involved in Aβ uptake.

Overexpression of wild type dynamin caused non-significant changes in Aβ internalization (Fig. 3, f and h versus b and d), but expression of the mutant dynamin K44A significantly reduced Aβ internalization and transport (Fig. 3, j versus f). In addition, overexpression of clathrin hub did not significantly affect Aβ internalization (Fig. 3, n versus b). These results suggest that Aβ is internalized by a mechanism that requires dynamin but is independent of clathrin. Importantly overexpression of clathrin hub in our experiments did block clathrin-dependent endocytosis as demonstrated by the dramatic decrease of LDL internalization when clathrin hub was overexpressed (Fig. 3, p versus d). Together these results indicate that dynamin is a central player in Aβ uptake and that clathrin is not involved in the process.

Caveolin Is Not Required for Aβ Endocytosis—Clathrin-mediated endocytosis targets proteins to the early endosomes (characterized by the presence of the protein EEA1) where proteins are sorted for either recycling or trafficking to late endosomes and lysosomes (42, 43). In contrast, caveolin-positive vesicles arise from caveolae and represent a non-clathrin internalization pathway (44). Co-localization with EEA1 and caveolin-1 has been used as indication of clathrin- and caveolae-mediated endocytosis, respectively (45).

Sympathetic neurons were given fluo-Aβ-(1–42) for 30 min, and the internalization compartments were analyzed by three-color immunofluorescence to simultaneously detect EEA1 (a marker of early endosomes), caveolin (a marker of the caveolae pathway), and Aβ-(1–42) (Fig. 4). Our data indicate that the majority of internalized Aβ-(1–42) did not co-localize with EEA1 or caveolin. As expected significant co-localization of EEA1 and caveolin was not observed either. These results corroborated that Aβ is internalized independently of clathrin and imply that Aβ-(1–42) internalization is independent of caveolin as well.


Figure 3
View larger version (105K):
[in this window]
[in a new window]

  		FIGURE 3.
Aβ internalization requires dynamin but is independent of clathrin. Rat sympathetic neurons cultured in three-compartment dishes were infected with recombinant adenovirus encoding wild type (WT) dynamin (e–h), dynamin (Dyn) K44A mutant (i–l), and clathrin (Cla) hub (m–p). After 72 h of protein expression, neurons were incubated with 5 µM fluo-Aβ-(1–42) or 50 µg/ml DiI-LDL in the distal axon-containing compartment. After 18 h, neurons were analyzed using a fluorescence microscope. Data are representative of two independent experiments with similar results.

 


Figure 4
View larger version (62K):
[in this window]
[in a new window]

  		FIGURE 4.
Internalized Aβ-(1–42) does not co-localize with caveolin or with markers of clathrin-mediated endocytosis. Rat neurons were incubated with fluo-Aβ-(1–42) (5 µM) for 1 h at 37 °C. After fixation EEA1 and caveolin were detected using the primary antibodies indicated under "Experimental Procedures" followed by an Alexa647-conjugated anti-rabbit antibody and an Alexa594-conjugated anti-mouse antibody, respectively. Cells were observed by confocal laser-scanning microscopy. Aβ, EEA1, and caveolin staining are colored green, red, and purple, respectively. Co-localization should appear yellow for Aβ/EEA1 and white for Aβ/caveolin. Significant co-localization of Aβ with EEA1 or caveolin was not observed.

 
To further investigate the requirement of caveolin, we examined Aβ-(1–42) internalization in neurons isolated from caveolin-1 knock-out (Cav1–/–) and from control ((B6 129 SF2/J) (Cav1+/+)) mice. Neurons that did not express caveolin-1 were able to internalize Aβ as effectively as neurons isolated from wild type mice (Fig. 5). This finding strongly indicates that caveolin is not necessary for Aβ internalization.

Aβ Internalization Depends on the Levels of Cellular Sphingolipids and Cholesterol—The results presented above and previous evidence from brains of AD patients indicating that Aβ is present in a complex with the lipid raft component GM1 (46) suggest that Aβ-(1–42) is internalized by caveolin-independent, lipid raft-mediated endocytosis. If so, Aβ-(1–42) should be sensitive to changes in the levels of cholesterol and/or sphingolipids (SPLs). To test this possibility we attempted to decrease membrane cholesterol. The most widely used way to achieve membrane cholesterol depletion is to perform short treatments (up to 30 min) with methyl-β-cyclodextrin. However, our experiments involved long incubations (up to 18 h) with Aβ during which time membrane cholesterol levels will likely return to normal. We therefore decided to inhibit cholesterol synthesis using pravastatin, a well known inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, which has already been tested in sympathetic neurons (47). The reduction of cellular SPLs was achieved by using the ceramide synthase inhibitor Fumonisin B1 (22). The inhibitors were given to neurons cultured in three-compartment dishes according to the scheme in Fig. 6A before adding fluo-Aβ-(1–42) in the axon-containing compartment. Parallel cultures were subjected to the same treatments with inhibitors but were given CTxB, a marker of lipids rafts endocytosis. Fumonisin B1 was added to all three compartments to ensure complete inhibition of SLP synthesis in both cell bodies and axons. On the other hand, cholesterol is synthesized exclusively in cell bodies, and therefore pravastatin was given only to the center compartment as before. Both inhibitors are effective in sympathetic neurons and do not have deleterious effects on neuronal survival under the conditions used here (47, 48). Inhibition of SPL synthesis or cholesterol alone did not decrease Aβ internalization (Fig. 6, B (f and j versus b) and C). However, Fumonisin B1 and pravastatin together caused significant reduction (~51%) in Aβ internalization (Fig. 6, B (n versus b) and C). All together our data indicate the requirement of cholesterol and SPLs for Aβ-(1–42) uptake. CTxB internalization was more sensitive to changes in cholesterol and SPLs alone than Aβ-(1–42) uptake (Fig. 6, B (g, h, k, l, o, and p) and C). Although pravastatin treatment caused a significant decrease in total cholesterol mass, which was similar to that obtained with methyl-β-cyclodextrin (Fig. 6D), when we examined cholesterol by filipin staining (Fig. 6E) we found that pravastatin caused a preferential decrease of intracellular rather than plasma membrane cholesterol. On the other hand methyl-β-cyclodextrin-treated neurons showed a dramatic decrease of cholesterol at the plasma membrane (Fig. 6E). This difference in the nature of the pool of cholesterol affected could explain the lack of effect of pravastatin alone in Aβ uptake.


Figure 5
View larger version (46K):
[in this window]
[in a new window]

  		FIGURE 5.
Aβ-(1–42) internalization does not require caveolin. Sympathetic neurons isolated from caveolin-1 knock-out (Cav1–/–) and control ((B6 129 SF2/J) (Cav1+/+)) mice were incubated with 5 µM bio-Aβ-(1–42) at 37 °C for different times. Internalized Aβ was analyzed after cleavage of the biotin moiety as described under "Experimental Procedures" and in the legend for Fig. 2. A, representative blots of intracellular bio-Aβ-(1–42). B, quantification of immunoblots was performed using the UNSCAN software. Data are given in arbitrary units. IB, immunoblot; P, precipitation.

 
We next examined the association of Aβ with CTxB, a marker of the lipid raft endocytic pathway (Fig. 7). We found that fluo-Aβ-(1–42) only partially co-localized with CTxB. In addition, partial co-localization between CTxB and caveolin was observed. As before no co-localization between Aβ-(1–42) and caveolin was present.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The molecular events involved in neuronal Aβ internalization in AD are mostly unknown, and any progress in this respect has the opportunity to identify potential therapeutic targets. The experiments reported herein demonstrated that, in the absence of apoE, Aβ-(1–42) is taken up and internalized into primary neurons by a regulated mechanism that is enriched in the axons and requires cholesterol and sphingolipid synthesis. Previous studies in cortical neurons have detected Aβ internalization in the absence of serum (49); however, in these studies a different preparation of Aβ was used, and the mechanism of Aβ uptake was not investigated.

Extracellular accumulation of Aβ represents the foundation of the amyloid cascade hypothesis (50). The importance of intraneuronal Aβ accumulation in the pathogenesis of AD has emerged more recently (51–53). Intraneuronal Aβ is present in brains of AD (6, 54, 55) and Down syndrome patients (7, 56, 57). Studies in animal models of AD also support the role of intraneuronal Aβ. In studies using transgenic mice harboring constructs that target Aβ either extracellularly or intracellularly, only the intracellular Aβ-producing transgenic mice developed neurodegeneration (58). In APP and presenilin-1 double transgenic mice, intraneuronal Aβ accumulation precedes plaque formation (59), and in the triple transgenic model long term potentiation abnormalities and cognitive dysfunctions correlate with the appearance of intraneuronal Aβ prior to the occurrence of plaques or tangles (10, 60).

Some evidence suggests that the intracellular pool of Aβ is derived from slow production from APP inside the cells (61–64). On the other hand, work by D'Andrea et al. (6) favors a mechanism that involves Aβ endocytosis. Moreover, in organotypic hippocampal slice cultures, Aβ-(1–42) gradually accumulates and is retained intact by field CA1 but not by other subdivisions, suggesting the existence of selective Aβ uptake by neurons at risk in AD (65). In addition, extracellular Aβ-(1–42) can increase levels of intraneuronal Aβ-(1–42) (66), and Aβ reuptake is important for Aβ accumulation in situ (67).

Current development of AD therapy has focused on the inhibition of Aβ production with one strategy being to inhibit {gamma}-secretase (68), the multienzyme complex responsible for APP intramembrane cleavage. Yet therapies that suppress this enzymatic activity might eliminate critical functions with dramatic deleterious consequences because other important proteins (Notch, CD-44, Erb4, and E-cadherin) are also substrates of {gamma}-secretase (52, 69). Therefore, neuronal Aβ internalization represents an attractive process to be targeted for drug intervention in AD independently or in conjunction with more selective {gamma}-secretase inhibitors.

Previous studies have demonstrated internalization of synthetic Aβ peptides in neurons of hippocampal slices (65, 70) and in neuronal models in culture (65, 71–73). Although the evidence supports the notion that endocytosis is involved in Aβ internalization, the molecular details of Aβ uptake were not addressed in those studies, and the precise Aβ points of entry were not investigated.

With respect to this last aspect, findings that oligomeric Aβ deposits are present preferentially on distal axons and synapses in Tg2576 mouse brain and in central nervous system-derived neuronal cells suggested that these structures are important sites of Aβ entry (14, 32). The use of the three-compartment culture system in our studies allowed us to directly examine Aβ uptake by axons because neurons are plated in the center compartment of the dish, which is over 1 mm wide; therefore neurites that grow in the side compartments represent axons exclusively (74). We demonstrated that Aβ-(1–42) is preferentially internalized through distal axons and retrogradely transported to cell bodies. To our knowledge, this is the first direct demonstration of more efficient uptake of Aβ by axons than by cell bodies. This result might have important implications in particular for basal forebrain neurons that differ from other neurons affected in AD in that their somas are located in nuclei that are physically distant from the areas of preferential Aβ accumulation in the cortex and hippocampus. In addition, we found that there is robust retrograde transport of Aβ to cell bodies, but the anterograde transport from cell bodies to axons was negligible. The limited Aβ internalization found when Aβ was added to the center compartment cannot be explained by the presence of less cellular membrane in this compartment because uptake of DiI-lipoproteins by cell bodies was observed in parallel experiments (not shown). Our system, however, does not permit the study of uptake by dendrites exclusively because the center compartment also contains cell bodies and proximal axons.


Figure 6
View larger version (68K):
[in this window]
[in a new window]

  		FIGURE 6.
Aβ internalization depends on cellular sphingolipids and cholesterol levels. Rat sympathetic neurons cultured in three-compartment cultures were left untreated (control) or pretreated with 25 µM Fumonisin B1 (FB1) for 2 days or/and 50 µM pravastatin (Prav) for 1 day followed by treatment with fluo-Aβ-(1–42) or CTxB according to the scheme shown in A. B, after 18 h, the fluorescence of the cell body-containing compartment was analyzed. Bar, 20 µm. C, fluorescence intensity in cell bodies of 200 neurons treated with Aβ was quantified using Northern Eclipse software. Statistical significance of differences between untreated and treated neurons is indicated by * and was evaluated by analysis of variance (p ≤ 0.001). The experiment was repeated twice with comparable results. D, sympathetic neurons cultured in 24-well plates were treated with 50 µM pravastatin for 1 day or 10 mM methyl-β-cyclodextrin (MβCD) for 30 min at 37 °C, and cholesterol mass was measured with the Amplex Red cholesterol determination kit. Data are expressed as means ± S.D. of three independent experiments. E, neurons were treated with pravastatin or methyl-β-cyclodextrin as in D, and cholesterol was labeled with 0.1 µg/ml filipin.

 
The difference in Aβ internalization by cell bodies and axons indicated that Aβ uptake in the absence of apoE is a regulated mechanism possibly mediated by proteins enriched in axons. Among a few receptors previously involved in Aβ uptake (23, 34, 75, 76) the {alpha}7nAChR seemed one of the most relevant. The most vulnerable neurons in AD appear to be those that abundantly express the {alpha}7nAChR such as neurons of hippocampus and cholinergic projection neurons from the basal forebrain (77, 78). Besides there is evidence indicating that Aβ-(1–42) interacts with {alpha}7nAChR with high affinity (79, 80), and some recent studies have suggested the involvement of {alpha}7nAchR in the internalization of Aβ-(1–42) by neuronal cells lines (34). However, we found that Aβ-(1–42) was unable to compete with {alpha}-BTx nicotinic receptor binding sites in neuronal membranes, and {alpha}-BTx did not affect Aβ-(1–42) internalization. Our results are in agreement with recent evidence indicating that Aβ-(1–42) does not directly interact with {alpha}7NAChR (35). The difference between our findings and those of Nagele et al. (34) might be due to the use of Aβ monomers and not oligomers and the presence of serum in their studies.


Figure 7
View larger version (71K):
[in this window]
[in a new window]

  		FIGURE 7.
Internalized Aβ-(1–42) partially co-localizes with cholera toxin subunit B. Rat neurons were incubated with fluo-Aβ-(1–42) (5 µM) together with 10 µg/ml Alexa594-conjugated CTxB in 0.1% bovine serum albumin for 30 min at 37 °C. After fixation caveolin was detected using the primary antibody indicated under "Experimental Procedures" followed by an Alexa647-conjugated anti-rabbit antibody. Cells were observed by confocal laser-scanning microscopy. Aβ, CTxB, and caveolin staining are colored green, red, and purple, respectively. Co-localization should appear yellow for Aβ/CTxB and white for Aβ/caveolin and for CTxB/caveolin. Limited co-localization of Aβ with CTxB was observed.

 


Figure 8
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 8.
Model for Aβ internalization in neurons. HDL, high density lipoprotein.

 
Because the complex Aβ-apoE is internalized by LDLr-related protein and related receptors we investigated the role of these receptors in Aβ internalization in the absence of lipoproteins. Members of the LDLr family are differentially distributed in cell bodies and distal axons of sympathetic neurons (36), and ligands of the LDLr family members (apoE and activated {alpha}2-microglobulin) associate with Aβ resulting in the internalization of the complex Aβ-ligand (75, 81–83). To our knowledge the role of the LDLr family in the uptake of Aβ in the absence of LDLr ligands has not been investigated. Our studies showed that RAP, a chaperone that universally blocks ligand binding to LDLr, had no effect on Aβ uptake, whereas it completely blocked LDL internalization under the same experimental conditions. This result indicates that when Aβ is not forming a complex with apoE or other ligands its internalization is not mediated by members of the LDLr family. Aβ uptake is not even mediated by clathrin-dependent mechanisms as indicated by Aβ uptake in neurons in which clathrin-mediated endocytosis had been abrogated by overexpression of the clathrin hub. Moreover, internalized Aβ did not co-localize with EEA1, a marker for clathrin-mediated endocytosis. Taken together these results suggest that although LDLr and {alpha}7nAChR have been implicated in neuronal internalization other mechanism(s) operate in axons for Aβ uptake.

However, our data do indicate that Aβ uptake entails endocytosis because neurons expressing the inactive mutant of dynamin exhibited reduced Aβ internalization. Caveolae/lipid raft-mediated endocytosis is the most important dynamin-dependent, clathrin-independent endocytic process (41). By confocal studies we demonstrated, however, that Aβ does not co-localize with caveolin but partially co-localizes with CTxB, suggesting that Aβ-(1–42) internalization involves non-caveolae, GM1-containing rafts. Normal Aβ uptake by neurons isolated from caveolin-1 null mice further indicates that caveolin is not required for Aβ internalization. Although caveolins are expressed in neurons, the existing evidence suggests that neurons lack caveolae, and therefore caveolins might participate in neuronal processes different from endocytosis (84). Nevertheless lipid raft caveolae-independent endocytosis also occurs in cells with caveolae (41).

Plasma membrane cholesterol and sphingolipid levels regulate raft-mediated endocytosis. Cholesterol has been linked to several processes that take place in AD including Aβ aggregation (85–88) and modulation of APP cleavage and Aβ production (89–91). On the other hand, very little information is available on the role of cholesterol in Aβ internalization. Here we provide evidence that Aβ internalization is dependent on the cellular levels of sphingolipids and cholesterol. We demonstrated that reduction of cellular cholesterol or sphingolipids levels alone is not sufficient to block Aβ internalization, but the simultaneous decrease in cholesterol and sphingolipids effectively reduced Aβ uptake and trafficking. Our experiments also indicated that independent reduction of cholesterol or sphingolipids results in decreased CTxB uptake demonstrating that the drug treatments were effective. Previous work indicated that cholesterol content regulates Aβ binding to the cell surface. Arispe and Doh (92) and Yip et al. (93) reported that reducing membrane cholesterol in PC12 cells results in increased incorporation of the peptide into the membrane. Conversely another group found that cholesterol depletion abolishes the binding of Aβ-(1–40) to PC12 cells (86). None of these studies investigated the role of cholesterol in Aβ internalization. However, our data for the requirement of functional dynamin for Aβ internalization and trafficking suggest that penetration of Aβ into the membrane bilayer is not required for Aβ uptake.

We propose a model in which free Aβ and Aβ bound to apoE and other ligands enter the neurons by different mechanisms (Fig. 8). The proportion of each pool of Aβ will be determined by the levels of Aβ in the extracellular space and by the efficiency of Aβ binding to apoE. In turn Aβ binding to apoE is regulated by the apoE isoform present. The model also predicts that at very high levels of Aβ the pool of free Aβ will become more significant than the pool of Aβ-apoE. The complex interplay of Aβ pools might explain the conflicting findings on the apoE isoform effects.


   FOOTNOTES
 
* This work was supported by grants from the Canadian Institutes of Health and Research and a personal donation from William Sim. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1 and 2. Back

1 To whom correspondence should be addressed: Dept. of Pharmacology, 9-28 Medical Science Bldg., Faculty of Medicine, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. Tel.: 780-492-5966; Fax: 780-492-4325; E-mail: elena.chaves{at}ualberta.ca.

2 The abbreviations used are: AD, Alzheimer disease; Aβ, β-amyloid peptide; APP, amyloid precursor protein; apoE, apolipoprotein E; {alpha}7nAChR,{alpha}7 nicotinic acetylcholine receptor; LDL, low density lipoprotein; LDLr, LDL receptor; NGF, nerve growth factor; NHS, N-hydroxysuccinimide; CTxB, cholera toxin subunit B; DiI, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate; {alpha}-BTx, {alpha}-bungarotoxin; fluo-Aβ-(1–42), fluorescein-labeled Aβ; bio-Aβ-(1–42), biotinylated Aβ; RAP, receptor-associated protein; DAX, distal axon-containing compartment; CB, cell body/proximal axon-containing compartment; GM1, Galβ1,3GalNAcβ1,4(Neu5Ac{alpha}2,3)Galβ1,4Glcβ1,1'-ceramide; SPL, sphingolipid; Cav1, caveolin-1. Back


   ACKNOWLEDGMENTS
 
We appreciate the excellent technical assistance of Laurie Moring. We are thankful to Dr. Jack Jhamandas and David MacTavish (University of Alberta) for providing the basal forebrain cholinergic neurons and to Dr. Edwin Daniel (University of Alberta) for providing us access to the caveolin null mice. We thank Honey Chan for helping with confocal and electron microscopy experiments.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Selkoe, D. J. (2001) J. Alzheimer's Dis. 3, 75–80[Medline] [Order article via Infotrieve]
  2. Selkoe, D. J. (1999) Nature 399, (suppl.) A23–A31[CrossRef][Medline] [Order article via Infotrieve]
  3. Skovronsky, D. M., Doms, R. W., and Lee, V. M. (1998) J. Cell Biol. 141, 1031–1039[Abstract/Free Full Text]
  4. Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., and Selkoe, D. J. (2000) Biochemistry 39, 10831–10839[CrossRef][Medline] [Order article via Infotrieve]
  5. Selkoe, D. J. (2004) Ann. Intern. Med. 140, 627–638[Free Full Text]
  6. D'Andrea, M. R., Nagele, R. G., Wang, H. Y., Peterson, P. A., and Lee, D. H. (2001) Histopathology 38, 120–134[CrossRef][Medline] [Order article via Infotrieve]
  7. Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H., and Yankner, B. A. (2002) Neuron 33, 677–688[CrossRef][Medline] [Order article via Infotrieve]
  8. Helguera, P., Pelsman, A., Pigino, G., Wolvetang, E., Head, E., and Busciglio, J. (2005) J. Neurosci. 25, 2295–2303[Abstract/Free Full Text]
  9. Zhang, Y., McLaughlin, R., Goodyer, C., and LeBlanc, A. (2002) J. Cell Biol. 156, 519–529[Abstract/Free Full Text]
  10. Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., and LaFerla, F. M. (2003) Neuron 39, 409–421[CrossRef][Medline] [Order article via Infotrieve]
  11. D'Andrea, M. R., Nagele, R. G., Wang, H. Y., and Lee, D. H. (2002) Neurosci. Lett. 333, 163–166[CrossRef][Medline] [Order article via Infotrieve]
  12. Takahashi, R. H., Milner, T. A., Li, F., Nam, E. E., Edgar, M. A., Yamaguchi, H., Beal, M. F., Xu, H., Greengard, P., and Gouras, G. K. (2002) Am. J. Pathol. 161, 1869–1879[Abstract/Free Full Text]
  13. Shie, F. S., LeBoeuf, R. C., and Jin, L. W. (2003) Neuroreport 14, 123–129[CrossRef][Medline] [Order article via Infotrieve]
  14. Kokubo, H., Kayed, R., Glabe, C. G., Saido, T. C., Iwata, N., Helms, J. B., and Yamaguchi, H. (2005) Brain Res. 1045, 224–228[Medline] [Order article via Infotrieve]
  15. Song, M. S., Saavedra, L., and de Chaves, E. I. (2006) Neurobiol. Aging 27, 1224–1238[CrossRef][Medline] [Order article via Infotrieve]
  16. Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., and Ikeda, K. (1991) Brain Res. 541, 163–166[CrossRef][Medline] [Order article via Infotrieve]
  17. Permanne, B., Perez, C., Soto, C., Frangione, B., and Wisniewski, T. (1997) Biochem. Biophys. Res. Commun. 240, 715–720[CrossRef][Medline] [Order article via Infotrieve]
  18. Wisniewski, T., Golabek, A., Matsubara, E., Ghiso, J., and Frangione, B. (1993) Biochem. Biophys. Res. Commun. 192, 359–365[CrossRef][Medline] [Order article via Infotrieve]
  19. Yang, D. S., Small, D. H., Seydel, U., Smith, J. D., Hallmayer, J., Gandy, S. E., and Martins, R. N. (1999) Neuroscience 90, 1217–1226[CrossRef][Medline] [Order article via Infotrieve]
  20. Gylys, K. H., Fein, J. A., Tan, A. M., and Cole, G. M. (2003) J. Neurochem. 84, 1442–1451[CrossRef][Medline] [Order article via Infotrieve]
  21. Yamauchi, K., Tozuka, M., Hidaka, H., Nakabayashi, T., Sugano, M., and Katsuyama, T. (2002) Ann. Clin. Lab. Sci. 32, 65–74[Abstract/Free Full Text]
  22. Song, M. S., and Posse de Chaves, E. I. (2003) Neuropharmacology 45, 1130–1150[CrossRef][Medline] [Order article via Infotrieve]
  23. Jhamandas, J. H., and MacTavish, D. (2004) J. Neurosci. 24, 5579–5584[Abstract/Free Full Text]
  24. Dahlgren, K. N., Manelli, A. M., Stine, W. B., Jr., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) J. Biol. Chem. 277, 32046–32053[Abstract/Free Full Text]
  25. Schagger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368–379[CrossRef][Medline] [Order article via Infotrieve]
  26. Samuel, N., Wonnacott, S., Lindstrom, J., and Futerman, A. H. (1997) Neurosci. Lett. 222, 179–182[CrossRef][Medline] [Order article via Infotrieve]
  27. Vaucher, E., Fluit, P., Chishti, M. A., Westaway, D., Mount, H. T., and Kar, S. (2002) Exp. Neurol. 175, 398–406[CrossRef][Medline] [Order article via Infotrieve]
  28. Altschuler, Y., Barbas, S. M., Terlecky, L. J., Tang, K., Hardy, S., Mostov, K. E., and Schmid, S. L. (1998) J. Cell Biol. 143, 1871–1881[Abstract/Free Full Text]
  29. Le, P. U., and Nabi, I. R. (2003) J. Cell Sci. 116, 1059–1071[Abstract/Free Full Text]
  30. Kuruvilla, R., Zweifel, L. S., Glebova, N. O., Lonze, B. E., Valdez, G., Ye, H., and Ginty, D. D. (2004) Cell 118, 243–255[CrossRef][Medline] [Order article via Infotrieve]
  31. Kokubo, H., Kayed, R., Glabe, C. G., and Yamaguchi, H. (2005) Brain Res. 1031, 222–228[CrossRef][Medline] [Order article via Infotrieve]
  32. Muresan, Z., and Muresan, V. (2006) Mol. Cell. Biol. 26, 4982–4997[Abstract/Free Full Text]
  33. Campenot, R. B. (1982) Dev. Biol. 93, 13–21[CrossRef][Medline] [Order article via Infotrieve]
  34. Nagele, R. G., D'Andrea, M. R., Anderson, W. J., and Wang, H. Y. (2002) Neuroscience 110, 199–211[CrossRef][Medline] [Order article via Infotrieve]
  35. Small, D. H., Maksel, D., Kerr, M. L., Ng, J., Hou, X., Chu, C., Mehrani, H., Unabia, S., Azari, M. F., Loiacono, R., Aguilar, M. I., and Chebib, M. (2007) J. Neurochem. 101, 1527–1538[CrossRef][Medline] [Order article via Infotrieve]
  36. Posse De Chaves, E. I., Vance, D. E., Campenot, R. B., Kiss, R. S., and Vance, J. E. (2000) J. Biol. Chem. 275, 19883–19890[Abstract/Free Full Text]
  37. Bu, G., and Marzolo, M. P. (2000) Trends Cardiovasc. Med. 10, 148–155[CrossRef][Medline] [Order article via Infotrieve]
  38. Bu, G., and Schwartz, A. L. (1998) Trends Cell Biol. 8, 272–276[CrossRef][Medline] [Order article via Infotrieve]
  39. Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232–21238[Abstract/Free Full Text]
  40. LaDu, M. J., Shah, J. A., Reardon, C. A., Getz, G. S., Bu, G., Hu, J., Guo, L., and van Eldik, L. J. (2000) J. Biol. Chem. 275, 33974–33980[Abstract/Free Full Text]
  41. Kirkham, M., and Parton, R. G. (2005) Biochim. Biophys. Acta 1745, 273–286[Medline] [Order article via Infotrieve]
  42. Rubino, M., Miaczynska, M., Lippe, R., and Zerial, M. (2000) J. Biol. Chem. 275, 3745–3748[Abstract/Free Full Text]
  43. Marsh, M., and McMahon, H. T. (1999) Science 285, 215–220[Abstract/Free Full Text]
  44. Pelkmans, L., Kartenbeck, J., and Helenius, A. (2001) Nat. Cell Biol. 3, 473–483[CrossRef][Medline] [Order article via Infotrieve]
  45. Di Guglielmo, G. M., Le Roy, C., Goodfellow, A. F., and Wrana, J. L. (2003) Nat. Cell Biol. 5, 410–421[CrossRef][Medline] [Order article via Infotrieve]
  46. Yanagisawa, K. (2005) Neuroscientist 11, 250–260[Abstract/Free Full Text]
  47. de Chaves, E. I., Rusinol, A. E., Vance, D. E., Campenot, R. B., and Vance, J. E. (1997) J. Biol. Chem. 272, 30766–30773[Abstract/Free Full Text]
  48. de Chaves, E. I., Bussiere, M., Vance, D. E., Campenot, R. B., and Vance, J. E. (1997) J. Biol. Chem. 272, 3028–3035[Abstract/Free Full Text]
  49. Ditaranto, K., Tekirian, T. L., and Yang, A. J. (2001) Neurobiol. Dis. 8, 19–31[CrossRef][Medline] [Order article via Infotrieve]
  50. Hardy, J. A., and Higgins, G. A. (1992) Science 256, 184–185[Free Full Text]
  51. Gouras, G. K., Almeida, C. G., and Takahashi, R. H. (2005) Neurobiol. Aging 26, 1235–1244[CrossRef][Medline] [Order article via Infotrieve]
  52. Cuello, A. C. (2005) Brain Pathol. 15, 66–71[Medline] [Order article via Infotrieve]
  53. Tseng, H. C., Zhou, Y., Shen, Y., and Tsai, L. H. (2002) FEBS Lett. 523, 58–62[CrossRef][Medline] [Order article via Infotrieve]
  54. Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., Greengard, P., and Relkin, N. R. (2000) Am. J. Pathol. 156, 15–20[Abstract/Free Full Text]
  55. Echeverria, V., and Cuello, A. C. (2002) Mol. Neurobiol. 26, 299–316[CrossRef][Medline] [Order article via Infotrieve]
  56. Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., and Troncoso, J. C. (2001) Arch. Pathol. Lab. Med. 125, 489–492[Medline] [Order article via Infotrieve]
  57. Mori, C., Spooner, E. T., Wisniewsk, K. E., Wisniewski, T. M., Yamaguch, H., Saido, T. C., Tolan, D. R., Selkoe, D. J., and Lemere, C. A. (2002) Amyloid 9, 88–102[Medline] [Order article via Infotrieve]
  58. LaFerla, F. M., Tinkle, B. T., Bieberich, C. J., Haudenschild, C. C., and Jay, G. (1995) Nat. Genet. 9, 21–30[CrossRef][Medline] [Order article via Infotrieve]
  59. Wirths, O., Multhaup, G., Czech, C., Blanchard, V., Tremp, G., Pradier, L., Beyreuther, K., and Bayer, T. A. (2001) Neurosci. Lett. 316, 145–148[CrossRef][Medline] [Order article via Infotrieve]
  60. Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., and LaFerla, F. M. (2005) Neuron 45, 675–688[CrossRef][Medline] [Order article via Infotrieve]
  61. Tienari, P. J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C. L., Dotti, C. G., and Beyreuther, K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4125–4130[Abstract/Free Full Text]
  62. Turner, R. S., Suzuki, N., Chyung, A. S., Younkin, S. G., and Lee, V. M. (1996) J. Biol. Chem. 271, 8966–8970[Abstract/Free Full Text]
  63. Xia, W., Zhang, J., Ostaszewski, B. L., Kimberly, W. T., Seubert, P., Koo, E. H., Shen, J., and Selkoe, D. J. (1998) Biochemistry 37, 16465–16471[CrossRef][Medline] [Order article via Infotrieve]
  64. Soriano, S., Chyung, A. S., Chen, X., Stokin, G. B., Lee, V. M., and Koo, E. H. (1999) J. Biol. Chem. 274, 32295–32300[Abstract/Free Full Text]
  65. Bahr, B. A., Hoffman, K. B., Yang, A. J., Hess, U. S., Glabe, C. G., and Lynch, G. (1998) J. Comp. Neurol. 397, 139–147[CrossRef][Medline] [Order article via Infotrieve]
  66. Glabe, C. (2001) J. Mol. Neurosci. 17, 137–145[CrossRef][Medline] [Order article via Infotrieve]
  67. Gylys, K. H., Fein, J. A., Yang, F., Miller, C. A., and Cole, G. M. (2007) Neurobiol. Aging 28, 8–17[CrossRef][Medline] [Order article via Infotrieve]
  68. Harrison, T., Churcher, I., and Beher, D. (2004) Curr. Opin. Drug Discov. Dev. 7, 709–719[Medline] [Order article via Infotrieve]
  69. Wolfe, M. S., and Kopan, R. (2004) Science 305, 1119–1123[Abstract/Free Full Text]
  70. Bi, X., Gall, C. M., Zhou, J., and Lynch, G. (2002) Neuroscience 112, 827–840[CrossRef][Medline] [Order article via Infotrieve]
  71. Burdick, D., Kosmoski, J., Knauer, M. F., and Glabe, C. G. (1997) Brain Res. 746, 275–284[CrossRef][Medline] [Order article via Infotrieve]
  72. Ida, N., Masters, C. L., and Beyreuther, K. (1996) FEBS Lett. 394, 174–178[CrossRef][Medline] [Order article via Infotrieve]
  73. Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., and Glabe, C. (1992) J. Biol. Chem. 267, 546–554[Abstract/Free Full Text]
  74. Campenot, R. B. (1982) Dev. Biol. 93, 1–12[CrossRef][Medline] [Order article via Infotrieve]
  75. Kang, D. E., Pietrzik, C. U., Baum, L., Chevallier, N., Merriam, D. E., Kounnas, M. Z., Wagner, S. L., Troncoso, J. C., Kawas, C. H., Katzman, R., and Koo, E. H. (2000) J. Clin. Investig. 106, 1159–1166[Medline] [Order article via Infotrieve]
  76. Kuner, P., Schubenel, R., and Hertel, C. (1998) J. Neurosci. Res. 54, 798–804[CrossRef][Medline] [Order article via Infotrieve]
  77. Breese, C. R., Adams, C., Logel, J., Drebing, C., Rollins, Y., Barnhart, M., Sullivan, B., Demasters, B. K., Freedman, R., and Leonard, S. (1997) J. Comp. Neurol. 387, 385–398[CrossRef][Medline] [Order article via Infotrieve]
  78. Dineley, K. T., Bell, K. A., Bui, D., and Sweatt, J. D. (2002) J. Biol. Chem. 277, 25056–25061[Abstract/Free Full Text]
  79. Wang, H. Y., Lee, D. H., Davis, C. B., and Shank, R. P. (2000) J. Neurochem. 75, 1155–1161[CrossRef][Medline] [Order article via Infotrieve]
  80. Wang, H. Y., Lee, D. H., D'Andrea, M. R., Peterson, P. A., Shank, R. P., and Reitz, A. B. (2000) J. Biol. Chem. 275, 5626–5632[Abstract/Free Full Text]
  81. Narita, M., Bu, G., Holtzman, D. M., and Schwartz, A. L. (1997) J. Neurochem. 68, 587–595[Medline] [Order article via Infotrieve]
  82. Jordan, J., Galindo, M. F., Miller, R. J., Reardon, C. A., Getz, G. S., and LaDu, M. J. (1998) J. Neurosci. 18, 195–204[Abstract/Free Full Text]
  83. Qiu, Z., Strickland, D. K., Hyman, B. T., and Rebeck, G. W. (1999) J. Neurochem. 73, 1393–1398[CrossRef][Medline] [Order article via Infotrieve]
  84. Head, B. P., and Insel, P. A. (2007) Trends Cell Biol. 17, 51–57[CrossRef][Medline] [Order article via Infotrieve]
  85. Schneider, A., Schulz-Schaeffer, W., Hartmann, T., Schulz, J. B., and Simons, M. (2006) Neurobiol. Dis. 23, 573–577[CrossRef][Medline] [Order article via Infotrieve]
  86. Wakabayashi, M., Okada, T., Kozutsumi, Y., and Matsuzaki, K. (2005) Biochem. Biophys. Res. Commun. 328, 1019–1023[CrossRef][Medline] [Order article via Infotrieve]
  87. Matsuzaki, K., and Horikiri, C. (1999) Biochemistry 38, 4137–4142[CrossRef][Medline] [Order article via Infotrieve]
  88. Kawarabayashi, T., Shoji, M., Younkin, L. H., Wen-Lang, L., Dickson, D. W., Murakami, T., Matsubara, E., Abe, K., Ashe, K. H., and Younkin, S. G. (2004) J. Neurosci. 24, 3801–3809[Abstract/Free Full Text]
  89. Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003) J. Cell Biol. 160, 113–123[Abstract/Free Full Text]
  90. Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., and Hartmann, T. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 5856–5861[Abstract/Free Full Text]
  91. Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., and Simons, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6460–6464[Abstract/Free Full Text]
  92. Arispe, N., and Doh, M. (2002) FASEB J. 16, 1526–1536[Abstract/Free Full Text]
  93. Yip, C. M., Elton, E. A., Darabie, A. A., Morrison, M. R., and McLaurin, J. (2001) J. Mol. Biol. 311, 723–734[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Sci SignalHome page
F.-F. Liao and H. Xu
Insulin Signaling in Sporadic Alzheimer's Disease
Sci. Signal., June 9, 2009; 2(74): pe36 - pe36.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. Mandrekar, Q. Jiang, C. Y. D. Lee, J. Koenigsknecht-Talboo, D. M. Holtzman, and G. E. Landreth
Microglia Mediate the Clearance of Soluble A{beta} through Fluid Phase Macropinocytosis
J. Neurosci., April 1, 2009; 29(13): 4252 - 4262.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. D. Buckingham, A. K. Jones, L. A. Brown, and D. B. Sattelle
Nicotinic Acetylcholine Receptor Signalling: Roles in Alzheimer's Disease and Amyloid Neuroprotection
Pharmacol. Rev., March 1, 2009; 61(1): 39 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. A. Hansson Petersen, N. Alikhani, H. Behbahani, B. Wiehager, P. F. Pavlov, I. Alafuzoff, V. Leinonen, A. Ito, B. Winblad, E. Glaser, et al.
The amyloid {beta}-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae
PNAS, September 2, 2008; 105(35): 13145 - 13150.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/49/35722    most recent
M701823200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saavedra, L.
Right arrow Articles by de Chaves, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saavedra, L.
Right arrow Articles by de Chaves, E. P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement